GB004, a Novel Gut-Targeted Prolyl Hydroxylase Inhibitor, Induces HIF-1a Target Genes and is Efficacious in Mouse Colitis

GB004, a Novel Gut-Targeted Prolyl Hydroxylase Inhibitor, Induces HIF-1a Target Genes and is Efficacious in Mouse Colitis

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study